Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211

Spremljeno u:
Bibliografski detalji
Izdano u:Blood Cancer J
Glavni autori: Usmani, S Z, Sexton, R, Ailawadhi, S, Shah, J J, Valent, J, Rosenzweig, M, Lipe, B, Zonder, J A, Fredette, S, Durie, B, Hoering, A, Bartlett, B, Orlowski, R Z
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2015
Teme:
Letter to the Editor
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4558587/
https://ncbi.nlm.nih.gov/pubmed/26252787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2015.62
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items